Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[177Lu]Lu-DOTA-(PEG28)2-A20FMDV2
- Development stage
- Preclinical
- Lead developer
- Washington University School of Medicine
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
[177Lu]Lu-DOTA-(PEG28)2-A20FMDV2 is a targeted radiopharmaceutical developed for the treatment of cancers overexpressing the integrin alpha-v beta-6 (avb6) receptor. It consists of the beta-emitting radioisotope Lutetium-177 complexed with a DOTA chelator and conjugated to a bi-terminally PEGylated version of the A20FMDV2 peptide. The A20FMDV2 peptide is a 20-amino-acid sequence derived from the foot-and-mouth disease virus that exhibits high affinity and selectivity for the avb6 receptor, which is frequently upregulated in aggressive malignancies such as pancreatic ductal adenocarcinoma. In preclinical studies, this specific non-albumin-binding formulation demonstrated rapid blood clearance and lower tumor uptake compared to albumin-binding derivatives, serving as a baseline therapeutic agent in the development of avb6-targeted theranostic pairs.
- Other names
- 177Lu-DOTA-(PEG28)2-A20FMDV2non-albumin DOTA-(PEG28)2-A20FMDV2
02
Targets
αVβ6 (Integrin αVβ6)
Beyond the preview
Go deeper on [177Lu]Lu-DOTA-(PEG28)2-A20FMDV2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [177Lu]Lu-DOTA-(PEG28)2-A20FMDV2.